HomeNationSerum Institute of India requests US to lift ban on export of...

Serum Institute of India requests US to lift ban on export of raw material required for production of Covishield

@the_news_21

Serum Institute of India has requested United States to lift ban on export of raw material required for production of Covishield. In a tweet Serum’s Chief Executive officer Adar Poonawalla tagged US President Joe Biden and requested to lift the embargo on raw material export out of United States. Covishield is the largest used covid vaccine in India. Besides this it is exported to various countries under Vaccine Matri.

Serum has signed a $750m agreement with CEPI (Coalition for Epidemic Preparedness Innovations ) and the Vaccine Alliance Gavi to support the manufacturing, procurement and distribution of 300 million doses of the vaccine. In addition, AstraZeneca reached a licensing agreement with SII to supply one billion doses for low and middle-income countries.

Subscribe to TheNews21

Stay Ahead with Independent Journalism

Investigations, political analysis and major national and global stories delivered directly to your inbox.

Stay Ahead with Independent Journalism

Investigations, political analysis and major national and global stories delivered directly to your inbox.

27 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

spot_img

@the_news_21

Serum Institute of India has requested United States to lift ban on export of raw material required for production of Covishield. In a tweet Serum’s Chief Executive officer Adar Poonawalla tagged US President Joe Biden and requested to lift the embargo on raw material export out of United States. Covishield is the largest used covid vaccine in India. Besides this it is exported to various countries under Vaccine Matri.

Serum has signed a $750m agreement with CEPI (Coalition for Epidemic Preparedness Innovations ) and the Vaccine Alliance Gavi to support the manufacturing, procurement and distribution of 300 million doses of the vaccine. In addition, AstraZeneca reached a licensing agreement with SII to supply one billion doses for low and middle-income countries.

Html code here! Replace this with any non empty text and that's it.

27 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

spot_img